Aforementioned Factors are expected to bolster the Mesenchymal Stem Cells Market Growth over the Forecast Period
According to Osteoporosis Canada,
approximately 1 in 5 men and 1 in 3 women experience an osteoporotic fracture
during their lifetime, and approximately 70 to 90% of the 30,000 hip fractures
that occur each year are caused by osteoporosis. In 2012, the cost of treating
osteoporosis in Canada was approximately US$ 4.0 billion, and it is anticipated
that this cost will increase in the coming years. Additionally, 9.0 million
people worldwide experience osteoporosis fractures each year, according to the
International Osteoporosis Foundation (IOF). Over the forecast period, the
aforementioned factors are anticipated to support the market growth for mesenchymal
stem cells.
Due to the rapid expansion of
technological innovations, high disposable incomes, and the well-equipped
healthcare facilities, North America and Asia Pacific are predicted to hold the
largest market shares, followed by Europe. These factors will contribute to the
growth and development of the Mesenchymal
Stem Cells market. The market for
MSCs is predicted to grow faster as a result of the transplantation of new
mesenchymal stem cells into cancer patients.
Cancer is the second leading
cause of death worldwide, accounting for approximately 9.6 million deaths in
2018, according to the World Health Organization (WHO) 2018 Factsheet.
According to the European Journal of Cancer, there were more than 3.9 million
new cases of cancer in Europe in 2018 and roughly 1.9 million cancer-related
deaths. While breast cancer was the fourth most common cause of cancer-related
deaths in the Asia Pacific region in 2012, accounting for about 9% of all
cancer-related deaths in the region, according to the National Center for
Biotechnology Information (NCBI), with an estimated 18.0% of female cases.
Comments
Post a Comment